Research programme: vascular endothelial growth factor inhibitors - EncysiveAlternative Names: Angiogenesis inhibitors research programme - Encysive; TBC 2576; Vascular endothelial growth factor inhibitors research programme - Encysive
Latest Information Update: 24 Aug 2006
At a glance
- Originator Encysive Pharmaceuticals
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 24 Aug 2006 Discontinued - Preclinical for Solid tumours in USA (unspecified route)
- 21 Jan 2002 Preclinical development for Solid tumours in USA (Unknown route)